Aldeyra Therapeutics Management
Management criteria checks 2/4
Aldeyra Therapeutics' CEO is Todd Brady, appointed in Jan 2012, has a tenure of 12.33 years. total yearly compensation is $3.68M, comprised of 15.8% salary and 84.2% bonuses, including company stock and options. directly owns 1.94% of the company’s shares, worth $4.85M. The average tenure of the management team and the board of directors is 3 years and 10.8 years respectively.
Key information
Todd Brady
Chief executive officer
US$3.7m
Total compensation
CEO salary percentage | 15.8% |
CEO tenure | 12.3yrs |
CEO ownership | 1.9% |
Management average tenure | 3yrs |
Board average tenure | 10.8yrs |
Recent management updates
Recent updates
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?
Feb 16Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?
Nov 06Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Mar 26Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?
Nov 19Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Sep 14Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
Aug 04Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?
Aug 03Aldeyra says trial for dry eye disease candidate reached key goals
Jul 12Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?
Apr 19Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts
Feb 17Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap
Dec 23Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?
Dec 22Revisiting Aldeyra Therapeutics
Sep 29Aldeyra Therapeutics: A New Approach To Ocular Inflammatory Diseases With Impressive Clinical Data
Jun 01Aldeyra Therapeutics EPS beats by $0.01
May 06Aldeyra's conjunctivitis treatment meets late-stage study main goals
Apr 27How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Did Insiders Buy, In The Last Year?
Feb 23Aldeyra announces reproxalap's late-stage dry eye disease trial design
Feb 04Aldeyra initiates stock offering
Jan 13Aldeyra rated buy at Citi on reproxalap trial results
Jan 08Aldeyra's reproxalap improves dry eye disease symptoms, run-in cohort shows
Jan 07How Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Do Institutions Own?
Jan 01CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | US$4m | US$581k | -US$38m |
Sep 30 2023 | n/a | n/a | -US$46m |
Jun 30 2023 | n/a | n/a | -US$52m |
Mar 31 2023 | n/a | n/a | -US$61m |
Dec 31 2022 | US$3m | US$559k | -US$62m |
Sep 30 2022 | n/a | n/a | -US$65m |
Jun 30 2022 | n/a | n/a | -US$66m |
Mar 31 2022 | n/a | n/a | -US$63m |
Dec 31 2021 | US$3m | US$547k | -US$58m |
Sep 30 2021 | n/a | n/a | -US$53m |
Jun 30 2021 | n/a | n/a | -US$46m |
Mar 31 2021 | n/a | n/a | -US$39m |
Dec 31 2020 | US$2m | US$544k | -US$38m |
Sep 30 2020 | n/a | n/a | -US$39m |
Jun 30 2020 | n/a | n/a | -US$49m |
Mar 31 2020 | n/a | n/a | -US$55m |
Dec 31 2019 | US$4m | US$523k | -US$61m |
Sep 30 2019 | n/a | n/a | -US$58m |
Jun 30 2019 | n/a | n/a | -US$50m |
Mar 31 2019 | n/a | n/a | -US$46m |
Dec 31 2018 | US$3m | US$506k | -US$39m |
Sep 30 2018 | n/a | n/a | -US$35m |
Jun 30 2018 | n/a | n/a | -US$29m |
Mar 31 2018 | n/a | n/a | -US$26m |
Dec 31 2017 | US$2m | US$473k | -US$22m |
Compensation vs Market: Todd's total compensation ($USD3.68M) is above average for companies of similar size in the US market ($USD1.62M).
Compensation vs Earnings: Todd's compensation has increased whilst the company is unprofitable.
CEO
Todd Brady (51 yo)
12.3yrs
Tenure
US$3,684,651
Compensation
Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 12.3yrs | US$3.68m | 1.94% $ 4.9m | |
Senior VP of Finance | 2yrs | US$974.07k | 0.060% $ 149.5k | |
Chief Development Officer | 3.3yrs | US$1.59m | 0.14% $ 342.8k | |
Vice President of Commercial Strategy & Operations | 2.6yrs | no data | no data | |
Head of Investor Relations | no data | no data | no data |
3.0yrs
Average Tenure
51yo
Average Age
Experienced Management: ALDX's management team is considered experienced (3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 19.3yrs | US$3.68m | 1.94% $ 4.9m | |
Independent Chair of the Board | 7.7yrs | US$221.98k | 0.21% $ 525.0k | |
Independent Director | 13.9yrs | US$190.40k | 0.048% $ 118.6k | |
Independent Director | 15yrs | US$194.07k | 0.025% $ 62.2k | |
Independent Director | 10.6yrs | US$195.66k | 0.040% $ 100.7k | |
Independent Director | 10.9yrs | US$174.22k | 0.027% $ 66.6k | |
Member of Retina Segment Scientific Advisory Board | no data | no data | no data | |
Member of Anterior Segment Scientific Advisory Board | 4.3yrs | no data | no data | |
Member of Anterior Segment Scientific Advisory Board | no data | no data | no data | |
Independent Director | 4.3yrs | US$174.22k | 0% $ 0 | |
Member of Anterior Segment Scientific Advisory Board | no data | no data | no data | |
Member of Anterior Segment Scientific Advisory Board | no data | no data | no data |
10.8yrs
Average Tenure
64yo
Average Age
Experienced Board: ALDX's board of directors are seasoned and experienced ( 10.8 years average tenure).